Protagonist Therapeutics
PTGX
140.92
+2.23
+1.61%
Protagonist Therapeutics
US · PTGX
#1570 by market cap
Listed 2016
140.92
+2.23
+1.61%
Live - 5344 symbols - heartbeat 370s ago
· 2026-10-08 04:39
Pre-market
141.00
+0.06%
After-hours
140.92
0.00%
- Market cap
- 9.12B
- P/E (TTM)i
- 136.82
- P/Bi
- 10.84
- EPSi
- -2.05
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on PTGX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 119.77% -0.06pp
- Institutions
- 428 +4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund80.25%
Hedge Fund25.78%
VC/PE Fund5.91%
Public Company4.69%
Private Company1.40%
Government Pension Fund0.97%
Individual/Insider0.60%
Family Office/Trust0.41%
Insurance Company0.32%
Top holders as of 2026-06-30
BlackRock
15.93% · 10.31M sh
Farallon Capital Management, L.L.C.
9.81% · 6.35M sh
RTW Investments, LP
7.82% · 5.06M sh
Vanguard Portfolio Management, LLC
5.61% · 3.63M sh
UBS Asset Management
5.42% · 3.51M sh
Wellington Management Group
5.28% · 3.42M sh
State Street Global Advisors
5.13% · 3.32M sh
Vanguard Capital Management, LLC
5.09% · 3.29M sh
Johnson & Johnson Innovation - JJDC, Inc.
3.78% · 2.45M sh
T. Rowe Price Group, Inc.
3.32% · 2.15M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Dinesh Patel | CEO, President, Secretary & Director | 0.44% |
| Harold Selick | Independent Chairperson | 0.09% |
| Arturo Molina | Chief Medical Officer | 0.02% |
| Bryan Giraudo | Independent Director | 0.02% |
| Sarah O’Dowd | Independent Director | 0.01% |
| William Waddill | Independent Director | 0.01% |
| Lewis Williams | Independent Director | 0.01% |
| Asif Ali | Executive VP & Chief Financial Officer | 0.00% |
| Suneel Gupta | Chief Development Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Asif Ali | Executive VP & Chief Financial Officer | Derivative Exercise and Sale | -58,629 | $12.17–141.78 |
| 2026-09-09 | Dinesh Patel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -125,000 | $21.58–146.18 |
| 2026-09-02 | Dinesh Patel | CEO, President, Secretary & Director | Other Disposition | -510 | -- |
| 2026-08-10 | Dinesh Patel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -100,000 | $21.58–149.11 |
| 2026-06-22 | William Waddill | Independent Director | Derivative Exercise and Sale | -9,000 | $16.54–117.94 |
| 2026-06-09 | William Waddill | Independent Director | Derivative Exercise and Sale | -9,000 | $11.80–107.68 |
| 2026-05-28 | William Waddill | Independent Director | Derivative Exercise and Sale | -9,000 | $11.80–99.64 |
| 2026-05-11 | Dinesh Patel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -75,000 | $21.58–100.12 |
| 2026-05-07 | Bryan Giraudo | Independent Director | Open Market Disposition | -23,130 | $100.00–100.07 |
| 2026-05-06 | Bryan Giraudo | Independent Director | Derivative Exercise and Sale | -36,000 | $6.45–100.14 |
| 2026-04-22 | Dinesh Patel | CEO, President, Secretary & Director | Other Disposition | -1,460 | -- |
| 2026-04-19 | Asif Ali | Executive VP & Chief Financial Officer | Open Market Disposition | -1,750 | $105.47 |
| 2026-03-25 | Harold Selick | Independent Chairperson | Derivative Exercise and Sale | -24,000 | $12.88–105.00 |
| 2026-03-25 | Arturo Molina | Chief Medical Officer | Derivative Exercise and Sale | -15,000 | $8.04–104.79 |
| 2026-03-25 | Asif Ali | Executive VP & Chief Financial Officer | Derivative Exercise and Sale | -24,765 | $12.17–104.24 |
| 2026-03-24 | Dinesh Patel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -54,700 | $8.58–101.00 |
| 2026-03-22 | Dinesh Patel | CEO, President, Secretary & Director | Other Disposition | -50,000 | -- |
| 2026-02-16 | Lewis Williams | Independent Director | Derivative Exercise and Sale | -18,000 | $10.84–82.42 |
| 2026-02-05 | William Waddill | Independent Director | Derivative Exercise and Sale | -20,000 | $8.31–83.68 |
| 2026-01-26 | Dinesh Patel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -48,273 | $4.21–84.59 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:39:03 · For reference only, not investment advice and not tailored to your situation.